Key facts
- This page summarizes Michel Lagarde's Form 4 filing for WEST PHARMACEUTICAL SERVICES INC (WST).
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 10 Sep 2026, 15:40.
Michel Lagarde - 08 Sep 2026 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- WST
- Reported as of
- 08 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Sep 2026, 15:40:17 UTC
- Prior SEC filing
- 10 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Louis Lalli, as an agent for Michel Lagarde
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michel Lagarde filed Form 4 for WEST PHARMACEUTICAL SERVICES INC (WST) on 10 Sep 2026.
Change
- Previous filing in this sequence was filed on 10 Sep 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001518973
Primary reporting owner
Lagarde Michel
- Relationship
- President and CEO, Director
- Address
- 530 HERMAN O. WEST DRIVE, EXTON
- Signature
- /s/ Louis Lalli, as an agent for Michel Lagarde
- Signature date
- 10 Sep 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WST
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +13,879
- Change %
- Price
- $0.000000*
- Shares after
- 13,879
- Date
- 08 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,879
- Exercise price
- $337.75
- Footnotes
- F1
WST
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +11,081
- Change %
- Price
- $0.000000*
- Shares after
- 11,081
- Date
- 08 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,081
- Exercise price
- $337.75
- Footnotes
- F1
WST
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +12,088
- Change %
- Price
- $0.000000*
- Shares after
- 12,088
- Date
- 08 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,088
- Exercise price
- $337.75
- Footnotes
- F2
WST
transaction
Derivative
Rst. Stock Unit
Award
- Transaction value
- Shares
- +6,200
- Change %
- Price
- $0.000000*
- Shares after
- 6,200
- Date
- 08 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,200
- Exercise price
- Footnotes
- F1, F3
WST
transaction
Derivative
Rst. Stock Unit
Award
- Transaction value
- Shares
- +4,950
- Change %
- Price
- $0.000000*
- Shares after
- 4,950
- Date
- 08 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,950
- Exercise price
- Footnotes
- F1, F3
WST
transaction
Derivative
Rst. Stock Unit
Award
- Transaction value
- Shares
- +3,600
- Change %
- Price
- $0.000000*
- Shares after
- 3,600
- Date
- 08 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,600
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This award vests in four equal annual installments beginning on September 8, 2027.
Footnote F2
This award cliff vests on September 8, 2031.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of WST common stock.